Clinical & Experimental Metastasis

, Volume 21, Issue 4, pp 331–338 | Cite as

Butyrate reduces liver metastasis of rat colon carcinoma cells in vivo and resistance to oxidative stress in vitro

  • Xiaotong Li
  • Idun M. Mikkelsen
  • Bente Mortensen
  • Jan-Olof Winberg
  • Nils-Erik Huseby

Abstract

Injection of the rat colon carcinoma cell line CC531 into spleen of syngeneic rats results in considerable amounts of liver metastases within 14 days. We investigated whether preincubation of the cells with butyrate reduced their metastatic ability in vivo and whether this was accompanied by reduction in related properties such as secretion of metalloproteinases and their ability to withstand oxidative stress. Butyrate incubation reduced cell growth rate and initiated apoptosis in a dose and time-related manner, but proliferation was retrieved when cultivation was continued in medium without butyrate. Splenic injection of butyrate treated, proliferating cells resulted in significantly reduced amounts of tumor mass compared to untreated cells. The butyrate treated cells were more susceptible to oxidative stress than control cells, as demonstrated by increased number of apoptotic cells and reduced cell growth after exposure to menadione. A reduction in cellular glutathione was found after prolonged incubation with butyrate. Butyrate appeared not to alter the secretion of active metalloproteinases from the cells although an apparent increase in proforms was demonstrated. Neither did butyrate alter the synthesis of metalloproteinase inhibitors. Lastly, a reduced adhesion of the tumor cells to collagen coated matrix was found after butyrate treatment. Thus, the inhibitory effects of butyrate on tumor malignancy are caused by a diversity of mechanisms.

cultured tumor cells metastatic potential butyrate apoptosis oxidative stress 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hague A, Manning AM, Hanlon KA et al. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993; 55: 498–505.PubMedGoogle Scholar
  2. 2.
    Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ 1997; 8: 523–32.PubMedGoogle Scholar
  3. 3.
    Wu JT, Archer SY, Hinnebusch B et al. Transient vs. prolonged histone hyperacetylation: effect on colon cancer cell growth, differentiation, and apoptosis. Am J Physiol Gastrointest Liver Physiol 2001; 280: G482–90.Google Scholar
  4. 4.
    Augeron C, Laboisse CL. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 1984; 44: 3961–9.PubMedGoogle Scholar
  5. 5.
    Ho SB, Yan PS, Dahiya R et al. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance. J Cell Physiol 1994; 160: 213–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Krupitza G, Grill S, Harant H et al. Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells. Br J Cancer 1996; 73: 433–8.PubMedGoogle Scholar
  7. 7.
    Smith TJ, Piscatelli JJ, Andersen V et al. n-Butyrate induces plas-minogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells. Hepatology 1996; 23: 866–71.PubMedGoogle Scholar
  8. 8.
    Emenaker NJ, Basson MD. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation. J Surg Res 1998; 76: 41–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Litvak DA, Evers BM, Hwang Ko et al. Butyrate-induced differentiation of Caco-2 cells is associated with apoptosis and early induction of p21Waf1/Cip1 and p27Kip1. Surgery 1998; 124: 161–9.PubMedGoogle Scholar
  10. 10.
    Gleave ME, Sato N, Sadar M et al. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 1998; 69: 271–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamamoto H, Fujimoto J, Okamoto E et al. Suppression of growth of hepatocellular carcinoma by sodium butyrate <Emphasis Type="Italic">in vitro</Emphasis> and <Emphasis Type="Italic">in viv</Emphasis>o.Int J Cancer 1998; 76: 897–902.PubMedCrossRefGoogle Scholar
  12. 12.
    Miyake H, Hara I, Yamanaka K et al. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer 1999; 79: 1651–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang HH, McIntosh AR, Hasinoff BB et al. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotox-icity: A natural hepatic defense against metastasis. Cancer Res 2000; 60: 5862–9.PubMedGoogle Scholar
  14. 14.
    Carretero J, Obrador E, Esteve JM et al. Tumoricidal activity of endothelial cells. Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion <Emphasis Type="Italic">in vitr</Emphasis>o. J Biol Chem 2001; 276: 25775–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Pompella A, Visvikis A, Paolicchi A et al. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 2003; 66: 1499–503.PubMedCrossRefGoogle Scholar
  16. 16.
    Anasagasti MJ, Martin JJ, Mendoza L et al. Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 1998; 27: 1249–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Meyer TE, Liang HQ, Buckley AR et al. Changes in glutathione redox cycling and oxidative stress response in the malignant progression of NB2 lymphoma cells. Int J Cancer 1998; 77: 55–63.PubMedCrossRefGoogle Scholar
  18. 18.
    Carretero J, Obrador E, Anasagasti MJ et al. Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clin Exp Metast 1999; 17: 567–74.CrossRefGoogle Scholar
  19. 19.
    Ortega AL, Carretero J, Obrador E et al. Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after <Emphasis Type="Italic">in vitro</Emphasis> interaction with the hepatic sinusoidal endothelium. J Biol Chem 2003; 278: 13888–97.PubMedCrossRefGoogle Scholar
  20. 20.
    Andreassen K, Mortensen B, Winberg JO, Huseby NE. Increased resistance towards oxidative stress accompanies enhancement of metastatic potential obtained by repeated <Emphasis Type="Italic">in vivo</Emphasis> passage of colon carcinoma cells in syngeneic rats. Clin Exp Metast 2002; 19: 623–9CrossRefGoogle Scholar
  21. 21.
    Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumor site. Int J Cancer 1984; 33: 689–92.PubMedGoogle Scholar
  22. 22.
    Li X, Mortensen B, Rushfeldt C, Huseby NE. Serum gamma-glutamyltransferase and alkaline phosphatase during experimental liver metastases. Detection of tumour-specific isoforms and factors affecting their serum levels. Eur J Cancer 1998; 34: 1935–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Svendsrud DH, Loennechen T, Winberg JO. Effect of adenosine analogues on the expression of matrix metalloproteinases and their inhibitors from human dermal fibroblasts. Biochem Pharmacol 1997; 53: 1511–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Winberg JO, Kolset SO, Berg E, Uhlin-Hansen L. Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J Mol Biol 2000; 304: 669–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Loennechen T, Mathisen B, Hansen J et al. Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner. Biochem Pharmacol 2003; 66: 2341–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Mathisen B, Lindstad RI, Hansen J et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metast 2003; 20: 701–11.CrossRefGoogle Scholar
  27. 27.
    Hattori S, Fujisaki H, Kiriyama T et al. Real-time zymography and reverse zymography: A method for detecting activities of matrix metalloproteinases and their inhibitors using FITC-labelled collagen and casein as substrates. Anal Biochem 2002; 301: 27–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Winberg JO, Gedde-Dahl T. Gelatinase expression in generalized epidermolysis bullosa simplex fibroblasts. J Invest Dermatol 1986; 87: 326–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Marks PA, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: Causes and therapies. Nature Reviews Cancer 2001; 1: 194–202.PubMedCrossRefGoogle Scholar
  30. 30.
    Archer SY, Meng S, Shei A, Hodin RA. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Hara I, Miyake H, Hara S et al. Sodium butyrate induced apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-fas-mediated cytotoxicity. Int J Oncol 2000; 17: 1213–8.PubMedGoogle Scholar
  32. 32.
    Lévy P, Robin H, Bertrand F et al. Butyratetreated colonic Caco-2 cells exhibit defective integrin-mediated signaling together with increased apoptosis and differentiation. J Cell Physiol 2003; 197: 336–47.PubMedCrossRefGoogle Scholar
  33. 33.
    Benard O, Balasubramanian KA. Modulation of glutathione level during butyrate-induced differentiation in human colon derived HT-29 cells. Mol Cell Biochem 1997; 170: 109–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Giardina C, Inan MS. Nonsteroidal anti-inflammatory drugs, short-chain fatty acids, and reactive oxygen metabolism in human colorectal cancer cells. Biochim Biophys Acta 1998; 1401: 277–88.PubMedCrossRefGoogle Scholar
  35. 35.
    Mikkelsen IM, Mortensen B, Laperche Y, Huseby NE. The expression of gamma-glutamyltransferase in rat colon carcinoma cells is distinctly regulated during differentiation and oxidative stress. Mol Cell Biochem 2002; 232: 87–95.PubMedCrossRefGoogle Scholar
  36. 36.
    Velazquez OC, Jabbar A, DeMatteo RP, Rombeau JL. Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice. Surgery 1996; 120: 440–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Cornelius LA, Nehring LC, Harding E et al. Matrix metalloproteinases generate angiostatin: effect on neovascularization. J Immunol 1998; 161: 6845–52.PubMedGoogle Scholar
  38. 38.
    Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998; 8: 171–7.PubMedGoogle Scholar
  39. 39.
    Yang JQ, Zhao W, Duan H et al. V-Ha-Ras oncogene upregulates the 92-kDa type IV collagenase (MMP-9) gene by increasing cellular superoxide production and activating NF-ê B. Free Rad Biol Med 2001; 31: 520–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Yoon SO, Park SJ, Yoon SY et al. Sustained production of H 2 O 2 activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phoshatidylinositol 3-kinase/NF-ê B pathway. J Biol Chem 2002; 277: 30271–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Wilson JR, Weiser MM. Colonic cancer cell (HT29) adhesion to laminin is altered by differentiation: Adhesion may involve galacto-syltransferase. Exp Cell Res 1992; 201: 330–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Buda A, Qualtrough D, Jepson MA et al. Butyrate downregulates á 2 â 1 integrin: A possible role in the induction of apoptosis in colorectal cancer cell lines. Gut 2003; 52: 729–34.PubMedCrossRefGoogle Scholar
  43. 43.
    Murphy G, Crabbe T. Gelatinases A and B. Meth Enzymol 1995; 248: 470–84.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Xiaotong Li
    • 1
  • Idun M. Mikkelsen
    • 1
  • Bente Mortensen
    • 1
  • Jan-Olof Winberg
    • 1
  • Nils-Erik Huseby
    • 1
  1. 1.Institute of Medical BiologyUniversity of TromsøNorway

Personalised recommendations